Beech Tree Labs herpes drug reaches milestone

BEECH TREE Labs recently announced that its in-development product BTL-tml had reached a milestone in its Phase 2 clinical trial.
BEECH TREE Labs recently announced that its in-development product BTL-tml had reached a milestone in its Phase 2 clinical trial.

PROVIDENCE – Beech Tree Labs recently announced that its in-development product BTL-tml had reached a milestone in its Phase 2 clinical trial.

Using sublingual drops, participants administered the medication to themselves with sublingual drops when they noticed first evidence of a herpes outbreak as characterized by tingling, itching, burning, or similar sensation.

More than 50 percent of all subjects experiencing initial symptoms were able to avoid lesion development by administering the drug, resulting in statistically significant difference between the patients receiving it and those receiving a placebo.

Beech Tree’s founder and CEO, Dr. John McMichael, said the results were promising.

- Advertisement -

“The results of our Phase 2 evaluations of BTL-tml for the treatment of recurrent oral herpes infections are encouraging and provide the impetus to identify a partner to move forward with pivotal Phase 3 trials,” McMichael said.

No posts to display